What is IQV's House Rating?

IQV scores 41 out of 100 (grade D) as of 2026-10-16, ranking #41 of 150 Health Care stocks we cover.

What do analysts say about IQV?

ThetaGrade's analyst-sentiment pillar for IQV scores 50/100 against its sector peers, which we read as mixed. This is our own derived score; we do not republish individual analyst ratings, counts or targets.

When does IQV report earnings next?

IQV's next earnings report is estimated for about 2026-10-27 (window 2026-10-20 to 2026-11-03), based on its past SEC 8-K earnings filings. This is an estimate, not a company-confirmed date.

ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.

IQV IQVIA

Health Care · Life Sciences Tools & Services · close $266.90 (2026-10-16) · latest quarter in EDGAR: 2026-03-31

#41/150 in sector · #299/964 overall

IQVIA (IQV) has a ThetaGrade House Rating of 41/100 (grade D), ranking #41 of 150 in Health Care. Its strongest pillars are cash flow (60) and valuation (57); its weakest is balance sheet (15). TTM revenue growth is 7.3% and operating margin 13.2%.

Data as of 2026-10-16.

Analyst sentiment

weight 7.5% · 50

Consensus score (1–5) (3.8%)	derived	89
90-day net rating shift (3.8%)	derived	29

Growth

weight 30.83% · 41

Revenue growth YoY (TTM) (12.3%)	7.3%	36
EPS growth YoY (TTM) (12.3%)	9.8%	45
Revenue acceleration (6.2%)	-1.8%	42

Profitability

weight 18.5% · 38

Operating margin (9.9%)	13.2%	53
4Q gross-margin change (8.6%)	-1.7%	20

Balance sheet

weight 18.5% · 15

Net debt / EBITDA (9.9%)	4.15×	15
Current ratio (4.9%)	0.75	1
Interest coverage (3.7%)	3.02×	35

Cash flow

weight 12.33% · 60

FCF margin (6.2%)	12.6%	50
FCF yield (6.2%)	4.6%	71

Valuation

weight 12.33% · 57

P/E (inverted) (6.2%)	33.16×	47
EV/Sales (inverted) (6.2%)	3.51×	66

Technicals (EOD)

RSI(14)	54.8
EMA 9 / 21	264.28 / 263.65 · crossed up 2d ago
200-day SMA	207.74
Volume vs 20d avg	0.67×
20-day return	-0.9%

Exit-rule monitor

EXITRating break: House Rating below 60
EXITBalance-sheet stress: net debt/EBITDA above 4×

Data source per metric (SEC XBRL tag or derivation): Revenue: RevenueFromContractWithCustomerExcludingAssessedTax · Gross profit: Revenue − CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization · Operating income: OperatingIncomeLoss · Interest expense: InterestExpense · D&A: DepreciationDepletionAndAmortization · EPS: EarningsPerShareDiluted · Market cap: SEC shares (dei EntityCommonStockSharesOutstanding (cover page)) × EOD close · P/E: EOD close ÷ SEC TTM EPS (EarningsPerShareDiluted).

Get rating changes like IQV's in the free Daily Brief

The market’s key events and signals, digested before the open.

✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
✓ OPEX, FOMC, CPI and jobs-day reminders

Free. Want more? See Premium (waitlist).

FAQ

What is IQV's House Rating?: IQV scores 41 out of 100 (grade D) as of 2026-10-16, ranking #41 of 150 Health Care stocks we cover.
What do analysts say about IQV?: ThetaGrade's analyst-sentiment pillar for IQV scores 50/100 against its sector peers, which we read as mixed. This is our own derived score; we do not republish individual analyst ratings, counts or targets.
When does IQV report earnings next?: IQV's next earnings report is estimated for about 2026-10-27 (window 2026-10-20 to 2026-11-03), based on its past SEC 8-K earnings filings. This is an estimate, not a company-confirmed date.
Is IQV a buy?: ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.

Sources: SEC EDGAR filings (fetched 2026-10-18), Finnhub recommendation trends, Massive EOD prices. Scores are sector percentiles; a factor without usable data is a data gap: it is left out and the remaining weights are renormalized (nothing is imputed). Educational only. Methodology